Molecular Formula | C18H20ClN5O4S |
Molar Mass | 437.9 |
Solubility | 10 mM in DMSO |
Storage Condition | -20℃ |
In vitro study | Voreloxin was able to effectively inhibit topoisomerase II relaxation with an IC50 of 3.2 μg/ml without affecting topoisomerase II cleavage. The cytotoxicity of Voreloxin against human tumor cell lines was more potent than that of etoposide. Voreloxin has broad antiproliferative activity against 15 cell lines, including 4 resistant cell lines, with an IC50 ranging from 0.04 to 1.155 μm. |
In vivo study | Voreloxin (50 mg/kg, I. P.) showed potent antitumor activity in mice implanted with P388 leukemia cells. In 10 (breast, ovarian, colon, lung, gastric, and melanin) xenograft models of 11 solid tumor species, 2 hematologic tumor xenograft models, voreloxin (25 mg/kg, I. V.) in 3 multidrug-resistant tumor models and 3 mouse homologous tumor xenograft models (colon 26,Lewis lung carcinoma, M5076 ovarian sarcoma) indicates strong tumor growth inhibition. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.284 ml | 11.418 ml | 22.836 ml |
5 mM | 0.457 ml | 2.284 ml | 4.567 ml |
10 mM | 0.228 ml | 1.142 ml | 2.284 ml |
5 mM | 0.046 ml | 0.228 ml | 0.457 ml |